Personal information

Emails & domains

Verified email domains

Other IDs

SciProfiles: 3174880

Activities

Collapse all

Employment (1)

LabCorp (United States): Buffalo, New York, US

Employment
Source: Self-asserted source
Paul DePietro

Works (8)

Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer

International Journal of Molecular Sciences
2024-04-26 | Journal article
DOI: 10.3390/ijms25094742
Contributors: Aditya Shreenivas; Daisuke Nishizaki; Suzanna Lee; Sarabjot Pabla; Mary Nesline; Jeffrey M. Conroy; Paul DePietro; Shumei Kato; Razelle Kurzrock
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy

Molecular Cancer Therapeutics
2023-11-01 | Journal article
DOI: 10.1158/1535-7163.MCT-23-0270
Contributors: Jessica Jou; Shumei Kato; Hirotaka Miyashita; Kartheeswaran Thangathurai; Sarabjot Pabla; Paul DePietro; Mary K. Nesline; Jeffrey M. Conroy; Eitan Rubin; Ramez N. Eskander et al.
Source: check_circle
Crossref

Data from Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy

2023-11-01 | Preprint
DOI: 10.1158/1535-7163.c.6908573
Contributors: Jessica Jou; Shumei Kato; Hirotaka Miyashita; Kartheeswaran Thangathurai; Sarabjot Pabla; Paul DePietro; Mary K. Nesline; Jeffrey M. Conroy; Eitan Rubin; Ramez N. Eskander et al.
Source: check_circle
Crossref

Data from Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy

2023-11-01 | Preprint
DOI: 10.1158/1535-7163.c.6908573.v1
Contributors: Jessica Jou; Shumei Kato; Hirotaka Miyashita; Kartheeswaran Thangathurai; Sarabjot Pabla; Paul DePietro; Mary K. Nesline; Jeffrey M. Conroy; Eitan Rubin; Ramez N. Eskander et al.
Source: check_circle
Crossref

Supplemental Figure 1 from Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy

2023-11-01 | Preprint
DOI: 10.1158/1535-7163.24474338
Contributors: Jessica Jou; Shumei Kato; Hirotaka Miyashita; Kartheeswaran Thangathurai; Sarabjot Pabla; Paul DePietro; Mary K. Nesline; Jeffrey M. Conroy; Eitan Rubin; Ramez N. Eskander et al.
Source: check_circle
Crossref

Supplemental Figure 1 from Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy

2023-11-01 | Preprint
DOI: 10.1158/1535-7163.24474338.v1
Contributors: Jessica Jou; Shumei Kato; Hirotaka Miyashita; Kartheeswaran Thangathurai; Sarabjot Pabla; Paul DePietro; Mary K. Nesline; Jeffrey M. Conroy; Eitan Rubin; Ramez N. Eskander et al.
Source: check_circle
Crossref

Supplementary Table 1 from Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy

2023-11-01 | Preprint
DOI: 10.1158/1535-7163.24474335.v1
Contributors: Jessica Jou; Shumei Kato; Hirotaka Miyashita; Kartheeswaran Thangathurai; Sarabjot Pabla; Paul DePietro; Mary K. Nesline; Jeffrey M. Conroy; Eitan Rubin; Ramez N. Eskander et al.
Source: check_circle
Crossref

Supplementary Table 1 from Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy

2023-11-01 | Preprint
DOI: 10.1158/1535-7163.24474335
Contributors: Jessica Jou; Shumei Kato; Hirotaka Miyashita; Kartheeswaran Thangathurai; Sarabjot Pabla; Paul DePietro; Mary K. Nesline; Jeffrey M. Conroy; Eitan Rubin; Ramez N. Eskander et al.
Source: check_circle
Crossref
How many people are using ORCID?